CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
Indianapolis, Indiana, United States and 164 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Indianapolis, Indiana, United States and 36 other locations
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...
Phase 3
Indianapolis, Indiana, United States and 222 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...
Phase 2
Indianapolis, Indiana, United States and 43 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Indianapolis, Indiana, United States and 33 other locations
menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase....
Phase 1, Phase 2
Indianapolis, Indiana, United States and 51 other locations
with Gemtuzumab Ozogamicin(GO) in subjects with relapsed/refractory acute myeloid leukemia. Using a standard 3+3 design, s...
Phase 1
Indianapolis, Indiana, United States and 3 other locations
or refractory (R/R) lymphomamultiple myelomanewly diagnosed acute myeloid leukemia (AML).This trial will be condu...
Phase 1
Indianapolis, Indiana, United States and 61 other locations
myeloid leukemia (AML) in transfusion-dependent participants with low or immediate-1 risk MDS that is relapsed/refractory...
Phase 2, Phase 3
Indianapolis, Indiana, United States and 126 other locations
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior in...
Phase 3
Indianapolis, Indiana, United States and 38 other locations
Clinical trials
Research sites
Resources
Legal